
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

November 15, 2006
Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of incorporation)

000-50614
(Commission File Number)

59-3410522
(IRS Employer
Identification No.)

13700 Progress Boulevard
Alachua, Florida 32615
(Address of principal executive offices including zip code)

(386) 418-4018
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 OTHER EVENTS.

On November 15, 2006, the Company issued a press release and a letter to friends of ONI announcing its intent to pursue licensing of its oral Probiotic mouth rinse following positive clinical results. A copy of the press release and letter are attached to this report as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

Item 9.01 FINANCIAL INFORMATION AND EXHIBITS**(d) Exhibits.**

<u>Number</u>	<u>Description</u>
99.1	Press Release dated November 15, 2006
99.2	Letter to friends of ONI dated November 15, 2006

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

November 15, 2006

ORAGENICS, INC.
(Registrant)

BY: /s/ Robert T. Zahradnik

Robert T. Zahradnik
President and Chief Executive Officer

FOR IMMEDIATE RELEASE**Oragenics to Pursue Licensing of its' Oral Probiotic Mouthrinse Following Positive Clinical Results**

ALACHUA, FL (November 15, 2006) – Oragenics, Inc. (AMEX:ONI) announced today that, as a result of the positive data from the clinical trial for its groundbreaking oral probiotic mouthrinse, it was advising a number of consultancy groups to submit plans for the sale or license of this technology. This action will allow Oragenics to focus on its other lead products currently under development, especially its new antibiotic, MU1140™, which has the potential to make a significant impact on the global anti-infectives market.

Based on review and analysis of the results, the trial met the company's primary clinical end point by demonstrating a substantial effect of Probiora3™ in reducing the levels of specific disease-causing bacteria in the mouths of young, healthy adult subjects. The same trends toward reductions in *Streptococcus mutans*, a bacterium that attacks teeth, and two bacterial strains associated with gum disease, *P. gingivalis* and *Campylobacter rectus*, were observed with both sets of subjects after only one week of product use. *C. rectus*, for example, was reduced to less than 1 % of its pretreatment plaque level. This trial also demonstrated that the Probiora3™ mouthrinse was safe and well-tolerated during the course of product use.

Dr. Raman Bedi, the former Chief Dental Officer for England and chairman of Oragenics' Scientific Advisory Committee, stated, "Probiora3™ is set to transform the multi-billion dollar worldwide antibacterial mouthwash market. The oral probiotic represents a breakthrough approach to maintaining oral health by utilizing cultures of bacteria commonly found in healthy mouths to provide a natural defense against those bacteria thought to be harmful to teeth and gums."

Dr. Robert Zahradnik, Oragenics' president and CEO, added, "Our clinically-supported probiotic-based approach to maintaining oral health appears to have a promising future. Probiora3's patent-pending blend of beneficial micro-organisms can be added to such products as mouthwashes and toothpastes, chewing gum, breath mints/lozenges, and quick-dissolve strips. The early licensing of this technology will allow partner(s) in the oral care and/or food and nutritional supplement industries to take this invention to market by the second half of 2007."

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas: infectious disease and oncology. Oragenics' core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections and obesity. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact:

Oragenics, Inc.
Robert T. Zahradnik, 386-418-4018 X222
www.oragenics.com

November 15, 2006

Dear Friends of ONI,

On October 16, 2006, I announced that the first of two sets of subjects had completed our Probiora3™ human study, and that we were pleased with the encouraging results obtained at that time. The second set of subjects have now completed the study protocol, and the results confirm our earlier conclusions and demonstrate that regular use of the Probiora3 mouthwash may beneficially impact on both dental and gingival health. More specifically, we met our primary endpoint by showing a substantial reduction in the levels of our targeted disease-causing bacteria in the mouths of the study subjects.

Orogenics will now actively pursue, both independently and with the help of consulting groups, the process of contacting potential regional and international partners in the oral care and/or food and nutritional supplement industries to determine interest and deal structure preferences for the rights to the Probiora3™ technology. We anticipate that the due diligence process could take about four months to complete before signing any deal for this technology. We are pleased that Probiora3™ has successfully completed this pivotal proof-of-concept clinical study and that it is the first product to enter the out-licensing stage for Orogenics.

If you have any questions about the Probiora3™ program, or if you have questions on other matters that impact our company, please do not hesitate to contact me directly.

Best Regards,

/s/ Robert T. Zahradnik, Ph.D.

Robert T. Zahradnik, Ph.D.